6MVQ image
Entry Detail
PDB ID:
6MVQ
Keywords:
Title:
HCV NS5B 1b N316 bound to Compound 31
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2018-10-26
Release Date:
2019-09-04
Method Details:
Experimental Method:
Resolution:
2.14 Å
R-Value Free:
0.23
R-Value Work:
0.21
R-Value Observed:
0.21
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:HCV Polymerase
Mutations:F101Y, K114R
Chain IDs:A, B
Chain Length:563
Number of Molecules:2
Biological Source:Hepatitis C virus subtype 1b
Ligand Molecules
Primary Citation

Abstact

We previously described the discovery of GSK5852 (1), a non-nucleoside polymerase (NS5B) inhibitor of hepatitis C virus (HCV), in which an N-benzyl boronic acid was essential for potent antiviral activity. Unfortunately, facile benzylic oxidation resulted in a short plasma half-life (5 h) in human volunteers, and a backup program was initiated to remove metabolic liabilities associated with 1. Herein, we describe second-generation NS5B inhibitors including GSK8175 (49), a sulfonamide- N-benzoxaborole analog with low in vivo clearance across preclinical species and broad-spectrum activity against HCV replicons. An X-ray structure of NS5B protein cocrystallized with 49 revealed unique protein-inhibitor interactions mediated by an extensive network of ordered water molecules and the first evidence of boronate complex formation within the binding pocket. In clinical studies, 49 displayed a 60-63 h half-life and a robust decrease in viral RNA levels in HCV-infected patients, thereby validating our hypothesis that reducing benzylic oxidation would improve human pharmacokinetics and lower efficacious doses relative to 1.

Legend

Protein

Chemical

Disease

Primary Citation of related structures